Sheet<u>1</u> of <u>1</u>

	_		ATTY, DOCKET NO.		APPLICATION NO.					
SUPPLEMENTAL LIST OF REFERENCES CITED BY					8449-128-999	09/668,724				
					APPLICANT					
APPLICANT					Srivastava, Pramod K.					
NOV 0 7 2007	(Use several sheets if necessary)				FILING DATE GROUP					
					September 22, 2000	1642				
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CI		CLASS	SUBCLASS	SS FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	LATION	
	<u> </u>							YES	МО	
< Y	DN	WO 00/54801	09/21/00	PCT					<u> </u>	
CY	DO	WO 02/07755	1/3/2002	PCT						
CY	DP	WO 94/14471	07/07/1994	PCT			=		<u></u>	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)										
CY	DQ	Agostoni et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.								
cy	DR	Bednar et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.								
CY	DS	Collen et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.								
cy	DT	Katsutani et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.								
CY	DU	Opekun et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-41.								
Cγ	DV	Reed et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.								
CY	DW	Zimecki et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.								
EXAMINER	CL	rupht	DATE	1-20-03						
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conference and not considered. Include copy of this form with next communication to applicant.									

NY2 - 1359101.1